BACKGROUND: Multiple clinical trials failed to demonstrate the efficacy of hydrocortisone, ascorbic acid, and thiamine (HAT) in sepsis. These trials were dominated by patients with pulmonary sepsis and have not accounted for differences in the inflammatory responses across varying etiologies of injury/illness. Hydrocortisone, ascorbic acid, and thiamine have previously revealed tremendous benefits in animal peritonitis sepsis models (cecal ligation and puncture [CLP]) in contradiction to the various clinical trials. The impact of HAT remains unclear in pulmonary sepsis. Our objective was to investigate the impact of HAT in pneumonia, consistent with the predominate etiology in the discordant clinical trials. We hypothesized that, in a pulmonary sepsis model, HAT would act synergistically to reduce end-organ dysfunction by the altering the inflammatory response, in a unique manner compared with CLP. METHODS: Using Pseudomonas aeruginosa pneumonia, a pulmonary sepsis model (pneumonia [PNA]) was compared directly to previously investigated intra-abdominal sepsis models. Machine learning applied to early vital signs stratified animals into those predicted to die (pDie) versus predicted to live (pLive). Animals were then randomized to receive antibiotics and fluids (vehicle [VEH]) vs. HAT). Vitals, cytokines, vitamin C, and markers of liver and kidney function were assessed in the blood, bronchoalveolar lavage, and organ homogenates. RESULTS: PNA was induced in 119 outbred wild-type Institute of Cancer Research mice (predicted mortality approximately 50%) similar to CLP. In PNA, interleukin 1 receptor antagonist in 72-hour bronchoalveolar lavage was lower with HAT (2.36 ng/mL) compared with VEH (4.88 ng/mL; p = 0.04). The remaining inflammatory cytokines and markers of liver/renal function showed no significant difference with HAT in PNA. PNA vitamin C levels were 0.62 mg/dL (pDie HAT), lower than vitamin C levels after CLP (1.195 mg/dL). Unlike CLP, PNA mice did not develop acute kidney injury (blood urea nitrogen: pDie, 33.5 mg/dL vs. pLive, 27.6 mg/dL; p = 0.17). Furthermore, following PNA, HAT did not significantly reduce microscopic renal oxidative stress (mean gray area: pDie, 16.64 vs. pLive, 6.88; p = 0.93). Unlike CLP where HAT demonstrated a survival benefit, HAT had no impact on survival in PNA. CONCLUSION: Hydrocortisone, ascorbic acid, and thiamine therapy has minimal benefits in pneumonia. The inflammatory response induced by pulmonary sepsis is unique compared with the response during intra-abdominal sepsis. Consequently, different etiologies of sepsis respond differently to HAT therapy.
BACKGROUND: Multiple clinical trials failed to demonstrate the efficacy of hydrocortisone, ascorbic acid, and thiamine (HAT) in sepsis. These trials were dominated by patients with pulmonary sepsis and have not accounted for differences in the inflammatory responses across varying etiologies of injury/illness. Hydrocortisone, ascorbic acid, and thiamine have previously revealed tremendous benefits in animal peritonitis sepsis models (cecal ligation and puncture [CLP]) in contradiction to the various clinical trials. The impact of HAT remains unclear in pulmonary sepsis. Our objective was to investigate the impact of HAT in pneumonia, consistent with the predominate etiology in the discordant clinical trials. We hypothesized that, in a pulmonary sepsis model, HAT would act synergistically to reduce end-organ dysfunction by the altering the inflammatory response, in a unique manner compared with CLP. METHODS: Using Pseudomonas aeruginosa pneumonia, a pulmonary sepsis model (pneumonia [PNA]) was compared directly to previously investigated intra-abdominal sepsis models. Machine learning applied to early vital signs stratified animals into those predicted to die (pDie) versus predicted to live (pLive). Animals were then randomized to receive antibiotics and fluids (vehicle [VEH]) vs. HAT). Vitals, cytokines, vitamin C, and markers of liver and kidney function were assessed in the blood, bronchoalveolar lavage, and organ homogenates. RESULTS: PNA was induced in 119 outbred wild-type Institute of Cancer Research mice (predicted mortality approximately 50%) similar to CLP. In PNA, interleukin 1 receptor antagonist in 72-hour bronchoalveolar lavage was lower with HAT (2.36 ng/mL) compared with VEH (4.88 ng/mL; p = 0.04). The remaining inflammatory cytokines and markers of liver/renal function showed no significant difference with HAT in PNA. PNA vitamin C levels were 0.62 mg/dL (pDie HAT), lower than vitamin C levels after CLP (1.195 mg/dL). Unlike CLP, PNA mice did not develop acute kidney injury (blood urea nitrogen: pDie, 33.5 mg/dL vs. pLive, 27.6 mg/dL; p = 0.17). Furthermore, following PNA, HAT did not significantly reduce microscopic renal oxidative stress (mean gray area: pDie, 16.64 vs. pLive, 6.88; p = 0.93). Unlike CLP where HAT demonstrated a survival benefit, HAT had no impact on survival in PNA. CONCLUSION: Hydrocortisone, ascorbic acid, and thiamine therapy has minimal benefits in pneumonia. The inflammatory response induced by pulmonary sepsis is unique compared with the response during intra-abdominal sepsis. Consequently, different etiologies of sepsis respond differently to HAT therapy.
Authors: Peter Q Eichacker; Chantal Parent; Andre Kalil; Claire Esposito; Xizhong Cui; Steven M Banks; Eric P Gerstenberger; Yvonne Fitz; Robert L Danner; Charles Natanson Journal: Am J Respir Crit Care Med Date: 2002-11-01 Impact factor: 21.405
Authors: Chanu Rhee; Raymund Dantes; Lauren Epstein; David J Murphy; Christopher W Seymour; Theodore J Iwashyna; Sameer S Kadri; Derek C Angus; Robert L Danner; Anthony E Fiore; John A Jernigan; Greg S Martin; Edward Septimus; David K Warren; Anita Karcz; Christina Chan; John T Menchaca; Rui Wang; Susan Gruber; Michael Klompas Journal: JAMA Date: 2017-10-03 Impact factor: 56.272
Authors: Jose Iglesias; Andrew V Vassallo; Vishal V Patel; Jesse B Sullivan; Joseph Cavanaugh; Yasmine Elbaga Journal: Chest Date: 2020-03-17 Impact factor: 9.410
Authors: Florin L Craciun; Kendra N Iskander; Evan L Chiswick; David M Stepien; Joel M Henderson; Daniel G Remick Journal: Shock Date: 2014-02 Impact factor: 3.454
Authors: Jonathan E Sevransky; Richard E Rothman; David N Hager; Gordon R Bernard; Samuel M Brown; Timothy G Buchman; Laurence W Busse; Craig M Coopersmith; Christine DeWilde; E Wesley Ely; Lindsay M Eyzaguirre; Alpha A Fowler; David F Gaieski; Michelle N Gong; Alex Hall; Jeremiah S Hinson; Michael H Hooper; Gabor D Kelen; Akram Khan; Mark A Levine; Roger J Lewis; Chris J Lindsell; Jessica S Marlin; Anna McGlothlin; Brooks L Moore; Katherine L Nugent; Samuel Nwosu; Carmen C Polito; Todd W Rice; Erin P Ricketts; Caroline C Rudolph; Fred Sanfilippo; Kert Viele; Greg S Martin; David W Wright Journal: JAMA Date: 2021-02-23 Impact factor: 56.272
Authors: Marcin F Osuchowski; Alfred Ayala; Soheyl Bahrami; Michael Bauer; Mihaly Boros; Jean-Marc Cavaillon; Irshad H Chaudry; Craig M Coopersmith; Clifford S Deutschman; Susanne Drechsler; Philip Efron; Claes Frostell; Gerhard Fritsch; Waldemar Gozdzik; Judith Hellman; Markus Huber-Lang; Shigeaki Inoue; Sylvia Knapp; Andrey V Kozlov; Claude Libert; John C Marshall; Lyle L Moldawer; Peter Radermacher; Heinz Redl; Daniel G Remick; Mervyn Singer; Christoph Thiemermann; Ping Wang; W Joost Wiersinga; Xianzhong Xiao; Basilia Zingarelli Journal: Shock Date: 2018-10 Impact factor: 3.454